TrialLancet (London, England)2009

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Philip D Home et al.PubMed ↗Publisher ↗

No numbers read from the abstract.